Bupropion hydrochloride produces conditioned hyperactivity in rats

Physiology and Behavior

Volumn 90, Issue 5, 2007, Pages 790-796

  Wilkinson, Jamie L ^a   Bevins, Rick A ^a  

^a UNIVERSITY OF NEBRASKA LINCOLN   (United States)

Author keywords

Activity; Individual differences; Locomotor; Nicotine; Pavlovian conditioning; Psychomotor stimulant; Sensitization; Smoking cessation; Wellbutrin ; Zyban

Indexed keywords

AMFEBUTAMONE;

ANIMAL EXPERIMENT; ARTICLE; BEHAVIOR CHANGE; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; ENVIRONMENTAL FACTOR; FOLLOW UP; HYPERACTIVITY; LOCOMOTION; MALE; MEDICAL LITERATURE; NONHUMAN; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; RAT;

EID: 33947591844     PISSN: 00319384     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.physbeh.2007.01.003     Document Type: Article

References (47)

1. Barrickman L.L., Perry P.J., Allen A.J., Kuperman S., Arndt S.V., Herrmann K.J., et al. Bupropion versus methylphenidate in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 34 (1995) 649-657
2. Cyr M., and Brown C.S. Current drug therapy recommendations for the treatment of attention deficit hyperactivity disorder. Drugs 56 (1998) 215-223
3. Ascher J.A., Cole J.O., Colin J.N., Feighner J.P., Ferris R.M., Fibiger H.C., et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry 56 (1995) 395-401
4. Ferris R.M., Cooper B.R., and Maxwell R.A. Studies of bupropions mechanism of antidepressant activity. J Clin Pschychiaty 44 (1983) 74-78
5. Fryer J.D., and Lukas R.J. Noncompetitive functional inhibition at diverse human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J Pharmacol Exp Ther 288 (1999) 88-92
6. Damaj M.I., Carroll F.I., Eaton J.B., Navarro H.A., Blough B.E., Mirza S., et al. Enantioselective effects of metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. Mol Pharmacol 66 (2004) 675-682
7. Miller D.K., Sumithran S.P., and Dwoskin L.P. Bupropion inhibits nicotine-evoked [(3)H] overflow from rat striatal slices preloaded with [(3)H]dopamine and from rat hippocampal slices preloaded with [(3)H]norepinephrine. J Pharmacol Exp Ther 302 (2002) 1113-1122
8. Slemmer J.E., Martin B.R., and Damaj M.I. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther 295 (2000) 321-327
9. Cooper B.R., Hester T.J., and Maxwell R.A. Behavioral and biochemical effects of the antidepressant bupropion (Wellbutrin): evidence for selective blockade of dopamine uptake in vivo. J Pharmacol Exp Ther 215 (1980) 127-134
10. Nomikos G.C., Damsma G., Wenkstern D., and Fibiger H.C. Effect of chronic bupropion on interstitial concentrations of dopamine in rat nucleus accumbens and striatum. Neuropsychopharmacology 7 (1992) 7-14
11. Ortmann R. The conditioned place preference paradigm in rats: effect of bupropion. Life Sci 37 (1985) 2021-2027
12. Wilkinson J.L., Palmatier M.I., and Bevins R.A. Pre-exposure to nicotine alters the subsequent locomotor stimulant effects of bupropion in rats. Nicotine Tob Res 8 (2006) 141-146
13. Nielsen J.A., Shannon N.J., Bero L., and Moore K.E. Effects of acute and chronic bupropion on locomotor activity and dopaminergic neurons. Pharmacol Biochem Behav 24 (1986) 795-799
14. Bevins R.A., Besheer J., and Pickett K.S. Nicotine-conditioned locomotor activity in rats: dopaminergic and GABAergic influences on conditioned expression. Pharmacol Biochem Behav 68 (2001) 135-145
15. Bevins R.A., and Peterson J. Individual differences in rats' reactivity to novelty and the unconditioned and conditioned locomotor effects of methamphetamine. Pharmacol Biochem Behavior 79 (2004) 65-74
16. Stewart J. Conditioned stimulus control of the expression of sensitization of the behavioral activating effects of opiate and stimulant drugs. In: Gormezano I., and Wasserman E.A. (Eds). Learning and memory: the behavioral and biological substrates (1992), LEA, New Jersey 129-151
17. Wise R.A., and Leeb K. Psychomotor-stimulant sensitization: a unitary phenomenon?. Behav Pharmacol 4 (1993) 339-349
18. Lamb R.J., and Griffiths R.R. Self-administration in baboons and the discriminative stimulus effects in rats of bupropion, nomifensine, diclofensine and imipramine. Psychopharmacology 102 (1990) 183-190
19. Tella S.E., Ladenheim B., and Cadet J.L. Differential regulation of dopamine transporter after chronic self-administration of bupropion and nomifensine. J Pharmacol Exp Ther 281 (1997) 508-513
20. Piazza P.V., Deminière J.M., LeMoal M., and Simon H. Factors that predict individual vulnerability to amphetamine self-administration. Science 245 (1989) 1511-1513
21. Deroche V., Piazza P.V., LeMoal M., and Simon H. Individual differences in psychomotor effects of morphine are predicted by reactivity to novelty and influenced by corticosterone secretion. Brain Res 623 (1993) 341-344
22. Gringas M.A., and Cools A.R. Analysis of the biphasic locomotor response to ethanol in high and low responders to novelty: a study in Nijmegen Wistar rats. Psychopharmacology 125 (1996) 258-264
23. Hooks M.S., Jones G.H., Liem B.J., and Justice J.B. Sensitization and individual differences to IP amphetamine, cocaine, or caffeine following repeated intracranial amphetamine infusions. Pharmacol Biochem Behav 43 (1992) 815-823
24. Jodogne C., Marinelli M., LeMoal M., and Piazza P.V. Animals predisposed to develop amphetamine self-administration show higher susceptibility to develop contextual conditioning of both amphetamine-induced hyperlocomotion and sensitization. Brain Res 657 (1994) 236-244
25. Kalinichev M., White D.A., and Holtzman S.G. Individual differences in locomotor reactivity to a novel environment and sensitivity to opioid drugs in the rat. I. Expression of morphine-induced locomotor sensitization. Psychopharmacology 177 (2004) 61-71
26. Dellu F., Mayo W., Vallée M., Maccari S., Piazza P.V., LeMoal M., et al. Behavioral reactivity to novelty during youth as a predictive factor of stress-induced corticosterone secretion in the elderly-a life-span study in rats. Psychoneuroendocrinology 21 (1996) 441-453
27. Piazza P.V., and LeMoal M. Pathophysiological basis of vulnerability to drug abuse: role of and interaction between stress, glucocorticoids, and dopaminergic neurons. Ann Rev Pharmacol Toxicol 36 (1996) 359-378
28. Bardo M.T., Donohew R.L., and Harrington N.G. Psychobiology of novelty seeking and drug seeking behavior. Behav Brain Res 77 (1996) 23-43
29. Bevins R.A. Novelty seeking and reward: implications for the study of high-risk behaviors. Curr Dir Psychol Sci 10 (2001) 189-193
30. Klebaur J.E., Bevins R.A., Segar T.M., and Bardo M.T. Individual differences in behavioral responses to novelty and amphetamine self-administration in female and male rats. Behav Pharmacol 12 (2001) 267-275
31. Besheer J., Palmatier M.I., Metschke D.M., and Bevins R.A. Nicotine as a signal for the presence or absence of sucrose reward: a Pavlovian drug appetitive conditioning preparation in rats. Psychopharmacology 172 (2004) 108-117
32. Cryan J.F., Bruijnzeel A.W., Skjei K.L., and Markou A. Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Psychopharmacology 168 (2003) 347-358
33. Jones C.N., Howard J.L., and McBennett S.T. Stimulus properties of antidepressants in the rat. Psychopharmacology 67 (1980) 111-118
34. Bevins R.A., Besheer J., Palmatier M.I., Jensen H.C., Pickett K.S., and Eurek S. Novel-object place conditioning: behavioral and dopaminergic processes in expression of novelty reward. Behav Brain Res 129 (2002) 41-50
35. Adams J.U., Careri J.M., Efferen T.R., and Rotrosen J. Conditioned locomotor stimulant effects of cocaine in rats do not result from interference with habituation. Psychopharmacology 151 (2000) 13-18
36. Barr G.A., Sharpless N.S., Cooper S., Schiff S.R., Paredes W., and Bridger W.H. Classical conditioning, decay and extinction of cocaine-induced hyperactivity and stereotypy. Life Sci 33 (1983) 1341-1351
37. Carey R.J., and Damianopoulos E.N. Conditioned cocaine induced hyperactivity: an association with increased medial prefrontal cortex serotonin. Behav Brain Res 62 (1994) 177-185
38. Mazurski E.J., and Beninger R.J. Effects of selective drugs for dopaminergic D1 and D2 receptors on conditioned locomotion in rats. Psychopharmacology 105 (1991) 107-112
39. Duvauchelle C.L., Ikegami A., and Castaneda E. Conditioned increases in behavioral activity and accumbens dopamine levels produces by IV cocaine. Behav Neurosci 114 (2000) 1156-1166
40. Gold L.H., Swerdlow N.R., and Koob G.F. The role of mesolimbic dopamine in conditioned locomotion produced by amphetamine. Behav Neurosci 102 (1988) 544-552
41. Exner M., and Clark D. Behaviour in the novel environment predicts responsiveness to d-amphetamine in the rat: a multivariate approach. Behav Pharmacol 4 (1993) 47-56
42. Hooks M.S., Jones G.H., Neill D.B., and Justice J.B. Individual differences in amphetamine sensitization: dose-dependent effects. Pharmacol Biochem Behav 41 (1991) 203-210
43. Piazza P.V., Maccari S., Deminiere J.M., LeMoal M., Mormede P., and Simon H. Corticosterone levels determine individual vulnerability to amphetamine self-administration. Proc Natl Acad Sci USA 88 (1991) 2088-2092
44. Knych E.T., and Eisenberg R.M. Effect of amphetamine on plasma corticosterone in the conscious rat. Neuroendocrinolgy 29 (1979) 110-118
45. Moldow R.L., and Fischman A.J. Cocaine induced secretion of ATCH, beta-endorphin, and corticosterone. Peptide 8 (1987) 819-822
46. Szumiinski K.K., Haskew R.E., Balogun M.Y., Maisonneuve I.M., and Glick S.D. Iboga compounds reverse the behavioral disinhibiting and corticosterone effects of acute methamphetamine: implications for their antiaddictive properties. Pharmacol Biochem Behav 69 (2001) 485-491
47. Piancentini M.F., Clinckers R., Meeusen R., Sarre S., Ebinger G., and Michotte Y. Effect of bupropion on hippocampal neurotransmitters and on peripheral hormonal concentrations in the rat. J Appl Physiol 95 (2003) 652-656